In China, the proportion of S. aureus isolates that were MRSA was 44.6% in 2014. The clinical and economic impact of MRSA in China remains largely uninvestigated. This study aims to compare the differences in hospital costs, length of hospital stay, and hospital mortality rate between MRSA and methicillin-susceptible S. aureus (MSSA) colonization or infection and between MRSA cases and those without an S. aureus infection. A retrospective and multicentre study was conducted in four tertiary hospitals in China between 2013 and 2015. Inpatient characteristics and hospital costs were collected from electronic medical records. We conducted propensity score matching (PSM) to eliminate selection bias by balancing the potential confounding variables between the two groups. The main indicators included hospital costs, length of hospital stay, and hospital mortality rate. A total of 1,335 inpatients with MRSA, 1,397 with MSSA, and 33,606 without an S. aureus infection were included. PSM obtained 954 and 1,313 pairs between the MRSA and MSSA groups and between the MRSA and S. aureus-free groups, respectively. After PSM, MRSA colonization or infection is associated with an increased total hospital cost ranging from $3,220 to $9,606, an excess length of hospital stay of 6 days-14 days, and an attributable hospital mortality rate of 0-3.58%. Between the MRSA and MSSA groups, MRSA colonization or infection was significantly associated with a higher total hospital cost and longer length of hospital stay among survivors but not among non-survivors; however, there were no differences in the hospital mortality rate between these two groups. Between the MRSA and the S. aureus-free groups, MRSA colonization or infection was significantly associated with an increased total hospital cost, a prolonged length of hospital stay and a higher hospital mortality rate among both survivors and non-survivors. It is critical to quantify the clinical and economic impact of MRSA to justify resource allocation for the development of strategies to improve clinical outcomes and to reduce the economic burden.
Patients and data collection. This was a retrospective and multicentre study. First, we included 100% of inpatients in hospital sites 1-3 and 60% of inpatients in hospital site 4 between 2013 and 2015 who had clinical samples positive for MRSA colonization or infection. The control group comprised clinical samples from inpatients with MSSA colonization or infection-positive clinical samples and inpatients without an S. aureus infection who were hospitalized during the same study period. To avoid duplication, only patients colonized and infected with the first episode of S. aureus detected were included in this study. Methicillin resistance was defined as resistance to anti-staphylococcal β-lactam antibiotics or cephamycins (oxacillin or cefoxitin) 2 .
Inpatient characteristics were collected from electronic medical records. Variables and dates relating to demographics (age, sex, and insurance), comorbidities (disease diagnosis, and Charlson comorbidity index (CCI) 39 ), hospital events (admitting service, surgical services, and dates of hospital and intensive care unit (ICU) admission/discharge), microbiological data, and clinical outcomes (death or alive during hospitalization) were extracted. Hospital costs were collected from electronic medical records as well.
Propensity score matching. We conducted propensity score matching (PSM) using STATA to eliminate selection bias by balancing the potential confounding variables between MRSA and MSSA cases and between MRSA cases and those without an S. aureus infection 40, 41 . We employed 1:1 nearest-neighbour matching to obtain matched pairs. MRSA was the dependent variable, and inpatient characteristics (age, sex and insurance), comorbidities, CCI, number of diagnoses, admission to the ICU, and surgery were independent variables. Then, we analysed the hospital cost, length of hospital stay, and hospital mortality rate using generated pairs. Indicators and data analyses. In this study, the main indicators included hospital costs, length of hospital stay, and hospital mortality rate. The total hospital cost for each inpatient's hospitalization was calculated, including the costs paid by both inpatients and health insurance, that is, the costs of health care. It comprised medication cost (antibiotic cost), diagnostic cost, treatment cost, material cost, and other costs. All hospital costs were presented in 2015 United States (US) $ values using the 2015 consumer price index of China and the purchasing power parities 42, 43 .
Hospital costs, length of hospital stay, and hospital mortality rate between MRSA and MSSA cases and between MRSA cases and those without an S. aureus infection were compared using Wilcoxon rank-sum test and χ 2 test and were described using median (95% confidence interval (CI)) and proportion (95% CI) for quantitative and qualitative variables, respectively. We also calculated the differences in hospital costs, length of hospital stay, and hospital mortality rate between the two groups, which are the incremental values due to MRSA. All tests were two-tailed, and p-values < 0.05 were determined to be statistically significant. Data analyses were performed with SAS software.
Ethical approval and informed consent. The study was approved by the institutional review board of
Zhejiang University School of Public Health, who waived the need for informed consent. All inpatients data were anonymized prior to analysis.
Results
A total of 1,335 inpatients with MRSA, 1,397 with MSSA, and 33,606 without an S. aureus infection were included in our study. Most of the inpatients were male (approximately 60%) and were covered by insurance (approximately 80%), and a small number of inpatients were admitted to the ICU or underwent surgery. The median ages were 74, 66, and 67 years old, the median number of diagnoses was 7, 6, and 5, and the median CCIs were 5, 4, and 4 for MRSA cases, MSSA cases, and those without an S. aureus infection, respectively (Tables 1-2) .
Compared with both inpatients with MSSA and those without an S. aureus infection, those with MRSA were significantly associated with an older age, a higher proportion of males, a higher number of diagnoses, a higher CCI, and a higher rate of admission to the ICU (Tables 1-2 ). In addition, MRSA patients were more likely to have insurance coverage and undergo surgery than those without an S. aureus infection ( Table 2 ). Some comorbidities between inpatients with MRSA and MSSA and between MRSA patients and those without an S. aureus infection were significantly different. Therefore, PSM was conducted to balance the characteristics between the two groups, and 954 and 1,313 pairs, respectively, were obtained (Tables 1-2). These pairs were subjected to analysis of the hospital costs, length of hospital stay, and hospital mortality rate. After PSM, there were no differences in baseline characteristics between the two groups.
Inpatients with MRSA were significantly associated with higher hospital costs than those with MSSA. The median differences (95% CI) in total hospital cost, antibiotic cost, medication cost, diagnostic cost, treatment cost, material cost, and other costs were $3,220 ($3,103-$3,393), $672 ($579-$723), $2,368 ($2,157-$2,633), $255 ($253-$278), $403 ($369-$413), $268 ($278-$295), and $8 ($6-$9), respectively. For surviving inpatients, the median differences in hospital costs were $3,182, $653, $2,373, $243, $429, $271, and $7, respectively. For non-surviving inpatients, there were significant differences in antibiotic cost, medication cost, and diagnostic cost, with median differences of $2,318, $3,078, and $382, respectively ( Table 3) .
Inpatients with MRSA were significantly associated with higher hospital costs than those without an S. aureus infection. The median differences (95% CI) in total hospital cost, antibiotic cost, medication cost, diagnostic cost, treatment cost, material cost, and other costs were $9,606 ($9,162-$10,575), $1,112 ($1,021-$1,210), $5,516 ($5,148-$5,870), $877 ($797-$986), $1,835 ($1,677-$1,975), $671 ($621-$725), and $7 ($6-$9), respectively. For surviving inpatients, the median differences in hospital costs were $9,336, $31,065, $5,354, $817, $1,771, $654, and $6, respectively. For non-surviving inpatients, there were significant differences in hospital costs except other costs, with median differences of $13,855, $3,631, $8,047, $1,851, $2,588, and $826, respectively ( Table 4 ).
The length of hospital stay was significantly longer for inpatients with MRSA than for inpatients with MSSA (27 days vs 21 days). There was a significant difference among surviving inpatients, with a median difference of 6 days, but no difference in non-surviving inpatients between the two groups (P = 0.0972). Compared with inpatients without an S. aureus infection, whether being a survivor or non-survivor, those with MRSA were significantly associated with a longer length of hospital stay, with median differences of 14 and 19 days, respectively (Table 5) .
Notably, regarding the hospital mortality rate, the difference between MRSA and MSSA inpatients was not significant (P = 0.265); however, there was a significant difference between MRSA cases and those without an S. aureus infection (4.80% (3.64-5.96%) vs 1.22% (0.63-1.81%), respectively) ( Table 6 ).
Discussion
To the best of our knowledge, this is the first multicentre study with a large sample size exploring the clinical and economic impact of MRSA in mainland China using the PSM method. It is also the first study to quantify the clinical and economic outcome of MRSA by comparing both MSSA inpatients and those without an S. aureus infection. It might be that the effect of methicillin resistance on clinical and economic outcomes among inpatients with S. aureus is underestimated after adjusting for the confounding factors between the MRSA and MSSA groups. Compared with inpatients without an S. aureus infection, however, the effect of MRSA is balanced. We found that after PSM, MRSA is associated with an increased total hospital cost ranging from $3,220 to $9,606, an excess length of hospital stay of 6 days-14 days, and an attributable hospital mortality rate of 0-3.58%. Among non-surviving inpatients, methicillin resistance does not independently increase the total hospital cost or length of hospital stay when the control group is MSSA. However, when the control group was inpatients without an S. aureus infection, MRSA was an independent factor for the total hospital cost or length of hospital stay among both survivors and non-survivors. Some studies reported that the difference in the total hospital cost and length of hospital stay for MRSA inpatients, compared with MSSA inpatients, are not significant 11, 34, 37 ; however, compared with inpatients without an S. aureus infection, they are significant 6, 21, 32 , which is consistent with our findings. Some studies conducted in China reported a 7.3 times higher median total hospital cost and 14 days longer median length of hospital stay among inpatients with MRSA than those without an S. aureus infection after controlling for some confounding factors 11 ; some studies only found significant differences between MRSA and MSSA patients using a univariate analysis, but not using a multivariate analysis 34, 35 .
The length of hospital stay is a major contributing factor to hospital costs 23 . In addition to an increase in daily bed cost, the prolonged length of hospital stay may be related to more treatment and diagnostic services, which yield substantial hospital costs; therefore, we did not include length of hospital stay in PSM analyses 44 . In the case of inpatients that die during hospitalization, their illness was more likely to be associated with critical illness; thus, there is a greater possibility that they will be admitted to the ICU, undergo more surgeries, and be treated with more diagnoses and more expensive medications, and these might contribute to increased hospital costs and length of hospital stay compared to surviving inpatients, but it this can attenuate the influence of methicillin resistance. Thus, we only found a significant difference in the total hospital cost and length of hospital stay among surviving inpatients between the MRSA and MSSA groups.
The hospital mortality rate between MRSA and MSSA inpatients has long been controversial, and the results in some studies are inconsistent 12, 16, 17, 20, 33, 40, 45, 46 . It was reported that patients with MRSA pneumonia infections had a higher mortality rate than those with MSSA (P < 0.001) 13 . In our study, we found that there were no differences in the hospital mortality rate between MRSA and MSSA inpatients; however, a significant difference existed between MRSA inpatients and those without an S. aureus infection, and this is consistent with some other studies conducted in China [34] [35] [36] 38 . Some studies in China reported a significantly higher hospital mortality for www.nature.com/scientificreports www.nature.com/scientificreports/ MRSA patients than those without an S. aureus infection (10.94% vs 4.43%) 38 ; however, there were no significant differences in hospital mortality between MRSA and MSSA patients after adjusting for confounding factors [34] [35] [36] .
A total of 67 non-surviving inpatients were included, including 29 inpatients with MRSA and 38 with MSSA. The small sample size may lack statistical power to detect significant differences; therefore, cohort studies with larger sample sizes among non-surviving inpatients in both the MRSA and MSSA groups are needed in future studies. In addition, MRSA and MSSA patients are usually empirically treated with vancomycin before the cultures are returned; however, when treated with vancomycin rather than beta-lactam agents, they showed a worse outcome for MSSA patients but a better outcome for MRSA patients 47 . Controlling the confounding factors using PSM can also be expected to bias the study towards a similar result between the MRSA and MSSA groups. Therefore, it is important to select variables in the PSM analysis. Some variables representing the severity of illness, including whether admitted to the ICU, whether undergoing surgery, complications or underlying disease, were included in the PSM analyses to decrease the influence of these variables on the main indicators; however, we excluded some variables that were directly related to hospital costs, such as length of hospital stay, length of ICU stay, and number of surgeries 44 , which is consistent with some studies 13, 48 . Some caution should be taken in the interpretation of these results.
The average total hospital cost, length of hospital stay, and hospital mortality were $3,042 and $2,470, 10.1 days and 9.4 days, 0.3% and 0.4% in Zhejiang and Shandong Provinces in 2015, respectively, which were similar to the national level ($2,378, 9.6 days, and 0.4%). Therefore, we assumed that the attributable total hospital cost, length of hospital stay, and hospital mortality due to MRSA from four hospitals in China were approximate results representing the national level. We also needed to expand this study to different types of hospitals in different areas in the future.
Certain limitations are worth considering in this study. First, due to the retrospective nature of our study, it is difficult to distinguish between colonization and infection, and ascertainment bias cannot be neglected. A stronger analysis needs to be conducted only in inpatients with a clinical infection in the future. In addition, in the PSM method, we only accounted for observable covariates regardless of other unobservable covariates; thus, there may remain some hidden biases after matching. Moreover, although it is a multicentre study, the data are from tertiary hospitals only and may not apply to other types of medical institutions.
conclusions
Between the MRSA and MSSA groups, MRSA colonization or infection was significantly associated with a higher total hospital cost and longer length of hospital stay among survivors but not among non-survivors. There were, however, no differences in the hospital mortality rate. Between the MRSA group and the S. aureus-free group, MRSA colonization or infection was significantly associated with an increased total hospital cost, a prolonged length of hospital stay and a higher hospital mortality rate among both survivors and non-survivors. It is critical to quantify the clinical and economic impact of MRSA to justify resource allocation for the development of strategies to improve clinical outcomes and to reduce the economic burden. Non-survivor   Median  95% CI  Median  95% CI  Median  95% CI   MSSA  21  20  23  21  20  23  20  12  26   MRSA  27  25  29  27  26  29  22  19  36   Difference  6  5  6  6  6  6  2  7 Table 6 . Hospital mortality rate among inpatients with MRSA and MSSA and among inpatients with MRSA and those without an S. aureus infection after PSM for potential confounding variables.
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